BR0312347A - Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato - Google Patents
Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilatoInfo
- Publication number
- BR0312347A BR0312347A BR0312347-2A BR0312347A BR0312347A BR 0312347 A BR0312347 A BR 0312347A BR 0312347 A BR0312347 A BR 0312347A BR 0312347 A BR0312347 A BR 0312347A
- Authority
- BR
- Brazil
- Prior art keywords
- coating material
- coating
- polymethacrylate
- active compound
- dissolving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA ORAL, E, USOS DA ESPESSURA DE REVESTIMENTO DE UM MATERIAL DE REVESTIMENTO DEPENDENTE DO PH DE DISSOLUçãO, DE UM MATERIAL DE REVESTIMENTO, E DE UM MATERIAL DE POLIMETACRILATO". Uma composição melhorada para o controle do perfil de liberação de um composto ativo ao longo do trato intestinal é composta de partículas, especialmente de grânulos, contendo o composto ativo, que são revestidos com um material de revestimento dependente do pH de dissolução ou um material de polimetacrilato, o qual de preferência, é dependente do pH de dissolução, até uma certa espessura, dependente do local e da taxa de liberação do componente ativo que é desejado. Em composições preferidas, dois ou mais conjuntos de partículas, nos quais cada conjunto é revestido com um material de revestimento dependente do pH de dissolução ou de um material de polimetacrilato até uma espessura diferente daquela de cada um dos outros conjuntos, são contidos dentro de uma cápsula revestida entericamente e produzem a liberação do composto ativo em vários locais desejados no trato intestinal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0215656A GB0215656D0 (en) | 2002-07-05 | 2002-07-05 | Controlled release composition |
GB0215657A GB0215657D0 (en) | 2002-07-05 | 2002-07-05 | Controlled release composition for the treatment of inflammatory bowel disease |
PCT/GB2003/002911 WO2004004696A1 (en) | 2002-07-05 | 2003-07-04 | Controlled release composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312347A true BR0312347A (pt) | 2005-04-12 |
Family
ID=30117101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312347-2A BR0312347A (pt) | 2002-07-05 | 2003-07-04 | Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato |
Country Status (15)
Country | Link |
---|---|
US (4) | US20060127484A1 (pt) |
EP (1) | EP1519717B1 (pt) |
JP (1) | JP2005532387A (pt) |
CN (1) | CN1665490A (pt) |
AT (1) | ATE482694T1 (pt) |
AU (1) | AU2003244840C1 (pt) |
BR (1) | BR0312347A (pt) |
CA (1) | CA2491355A1 (pt) |
DE (1) | DE60334378D1 (pt) |
DK (1) | DK1519717T3 (pt) |
MX (1) | MXPA05000128A (pt) |
NZ (1) | NZ537632A (pt) |
PL (1) | PL374922A1 (pt) |
RU (1) | RU2336865C2 (pt) |
WO (1) | WO2004004696A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
AU2004305293A1 (en) | 2003-12-23 | 2005-07-07 | Temrel Limited | Process for producing pellets for pharmaceutical compositions |
US10282785B1 (en) | 2004-11-19 | 2019-05-07 | Allstate Insurance Company | Delivery of customized insurance products and services |
US9875508B1 (en) | 2004-11-19 | 2018-01-23 | Allstate Insurance Company | Systems and methods for customizing insurance |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
CA2882048C (en) | 2006-02-03 | 2020-03-24 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
WO2007095092A2 (en) | 2006-02-09 | 2007-08-23 | Alba Therapeutics Corporation | Formulations for a tight junction effector |
AU2012203787B2 (en) * | 2006-02-09 | 2014-07-10 | Alba Therapeutics Corporation | Formulations for a Tight Junction Effector |
PL2679228T3 (pl) | 2006-06-21 | 2018-07-31 | Opko Ireland Global Holdings, Ltd. | Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D |
US20090069247A1 (en) | 2006-10-06 | 2009-03-12 | Blake Paterson | Use of tight junction antagonists to treat inflammatory bowel disease |
WO2008052185A2 (en) | 2006-10-26 | 2008-05-02 | Alba Therapeutics Corp | Materials and methods for the treatment of celiac disease |
US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
ES2403107T3 (es) | 2007-04-25 | 2013-05-14 | Cytochroma Inc. | Método de tratamiento de insuficiencia y deficiencia de vitamina D |
WO2008134523A1 (en) | 2007-04-25 | 2008-11-06 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
EP3542792B1 (en) | 2007-04-25 | 2023-06-28 | EirGen Pharma Ltd. | Controlled release 25-hydroxyvitamin d |
GB0712316D0 (en) * | 2007-06-26 | 2007-08-01 | Entripneur Ltd | A novel powder and its method of manufacture |
US20090036414A1 (en) * | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
US8962239B2 (en) | 2008-04-02 | 2015-02-24 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
EP2368546A4 (en) * | 2008-11-07 | 2013-11-20 | Samyang Biopharmaceuticals | PHARMACEUTICAL COMPOSITION WITH PROGRESSIVE RELEASE OF METHYLPHENIDATE |
US20100143437A1 (en) * | 2008-12-09 | 2010-06-10 | Morris Edward J | Implantable analgesic |
EP2298321A1 (en) * | 2009-08-26 | 2011-03-23 | Nordic Pharma | Novel pharmaceutical compositions for treating IBD |
CN105394354A (zh) * | 2010-01-15 | 2016-03-16 | 凯敏工业公司 | 受保护的α-淀粉酶 |
HUE048464T2 (hu) | 2010-03-29 | 2020-07-28 | Opko Ireland Global Holdings Ltd | Módszerek és készítmények mellékpajzsmirigy szintjének csökkentésére |
KR101423237B1 (ko) * | 2010-05-04 | 2014-07-30 | 주식회사 삼양바이오팜 | 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제 |
SG194605A1 (en) * | 2011-05-06 | 2013-12-30 | Glaxosmithkline Llc | Sustained release paracetamol formulations |
US8951996B2 (en) * | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
JP2014529630A (ja) * | 2011-09-07 | 2014-11-13 | ザウラー−ブロシュ、ローラント | 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤 |
US10653631B2 (en) | 2011-09-07 | 2020-05-19 | Roland SAUR-BROSCH | Optimal colon targeting technology |
GB201210184D0 (en) * | 2012-06-11 | 2012-07-25 | Univ Leuven Kath | Formulations of metronidazole for the treatment of pouchitis |
US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
CA2957240A1 (en) | 2014-08-07 | 2016-02-11 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
EP3162362A1 (de) * | 2015-10-30 | 2017-05-03 | Dr. Falk Pharma Gmbh | Optimierte mesalazinhaltige hochdosistablette |
JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンd治療法 |
JP2019534300A (ja) * | 2016-11-09 | 2019-11-28 | エンジーン,インコーポレイティド | プログラム細胞死リガンド1の腸管発現 |
US20200253506A1 (en) * | 2016-12-14 | 2020-08-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
CN116869457A (zh) | 2016-12-14 | 2023-10-13 | 比奥拉治疗股份有限公司 | 使用jak抑制剂治疗胃肠道疾病及装置 |
CA3045307A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
CN108822816A (zh) * | 2018-06-25 | 2018-11-16 | 中国石油集团渤海钻探工程有限公司 | 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法 |
CN113929807B (zh) * | 2021-06-25 | 2022-09-27 | 贵州省欣紫鸿药用辅料有限公司 | 一种烯烃酸树脂及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
US5834024A (en) * | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
JPH1067657A (ja) * | 1996-06-18 | 1998-03-10 | Otsuka Pharmaceut Co Ltd | マルチプルユニット型持続性製剤 |
DE19652183C1 (de) * | 1996-12-14 | 1998-02-12 | Schaper & Bruemmer Gmbh | Verwendung eines Extraktes aus Cimicifuga racemosa |
DE19724696A1 (de) * | 1997-06-12 | 1998-12-24 | Hexal Ag | Pharmazeutische Zubereitung mit drei Pelletarten |
EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
ATE438418T1 (de) * | 2001-05-01 | 2009-08-15 | Av Topchiev Inst Petrochemical | Hydrogel-zusammensetzungen |
-
2003
- 2003-07-04 AU AU2003244840A patent/AU2003244840C1/en not_active Ceased
- 2003-07-04 US US10/516,950 patent/US20060127484A1/en not_active Abandoned
- 2003-07-04 WO PCT/GB2003/002911 patent/WO2004004696A1/en active Application Filing
- 2003-07-04 DK DK03738316.3T patent/DK1519717T3/da active
- 2003-07-04 BR BR0312347-2A patent/BR0312347A/pt not_active IP Right Cessation
- 2003-07-04 DE DE60334378T patent/DE60334378D1/de not_active Expired - Lifetime
- 2003-07-04 AT AT03738316T patent/ATE482694T1/de not_active IP Right Cessation
- 2003-07-04 JP JP2004518982A patent/JP2005532387A/ja active Pending
- 2003-07-04 CA CA002491355A patent/CA2491355A1/en not_active Abandoned
- 2003-07-04 CN CN038159759A patent/CN1665490A/zh active Pending
- 2003-07-04 PL PL03374922A patent/PL374922A1/xx not_active Application Discontinuation
- 2003-07-04 RU RU2005102838/15A patent/RU2336865C2/ru not_active IP Right Cessation
- 2003-07-04 NZ NZ537632A patent/NZ537632A/en not_active IP Right Cessation
- 2003-07-04 EP EP03738316A patent/EP1519717B1/en not_active Revoked
- 2003-07-04 MX MXPA05000128A patent/MXPA05000128A/es active IP Right Grant
-
2011
- 2011-04-05 US US13/079,956 patent/US20110182986A1/en not_active Abandoned
-
2013
- 2013-04-15 US US13/863,132 patent/US20130230588A1/en not_active Abandoned
-
2014
- 2014-07-09 US US14/326,517 patent/US20140322317A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003244840A1 (en) | 2004-01-23 |
RU2005102838A (ru) | 2005-08-10 |
AU2003244840B2 (en) | 2009-09-10 |
MXPA05000128A (es) | 2005-09-30 |
US20130230588A1 (en) | 2013-09-05 |
DE60334378D1 (de) | 2010-11-11 |
DK1519717T3 (da) | 2011-01-10 |
CN1665490A (zh) | 2005-09-07 |
US20110182986A1 (en) | 2011-07-28 |
US20140322317A1 (en) | 2014-10-30 |
US20060127484A1 (en) | 2006-06-15 |
EP1519717A1 (en) | 2005-04-06 |
EP1519717B1 (en) | 2010-09-29 |
CA2491355A1 (en) | 2004-01-15 |
ATE482694T1 (de) | 2010-10-15 |
AU2003244840C1 (en) | 2010-03-04 |
RU2336865C2 (ru) | 2008-10-27 |
PL374922A1 (en) | 2005-11-14 |
WO2004004696A1 (en) | 2004-01-15 |
JP2005532387A (ja) | 2005-10-27 |
NZ537632A (en) | 2006-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312347A (pt) | Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato | |
DK1480624T3 (da) | Farmaceutisk tablet | |
WO2004112756A8 (en) | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | |
MX9701465A (es) | Formulacion de acetaminofeno, de liberacion sostenida. | |
DE60103186D1 (de) | Stossweise freisetzende Arzneiabgabesysteme | |
BR0103033A (pt) | Partìculas farmacêuticas de sabor mascarado | |
NO20016108L (no) | Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger | |
WO2004062577A3 (en) | Two or more enteric materials to regulate drug release | |
RS52798B (en) | PHARMACEUTICAL DOSAGE FORMS | |
DK1578406T3 (da) | Farmaceutisk sammensætning med modificeret frigivelse | |
MY148475A (en) | Controlled release preparations comprising tramadol and topiramate | |
WO2008132710A3 (en) | Pharmaceutical nimodipine compositions | |
HK1126394A1 (en) | Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent | |
HUP0203451A2 (hu) | Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra | |
WO2005097064A3 (en) | Taste-masked drugs in rupturing multiparticulates | |
AP2002002410A0 (en) | Hydrodynamically Balancing Oral Drug Delivery System | |
WO2006040779A3 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
EA200300110A1 (ru) | Композиция элетриптана в виде частиц | |
WO2004062552A3 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
ATE341312T1 (de) | Orale pharmazeutische zusammensetzung mit verzögerter freisetzung | |
BR0001144B1 (pt) | Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase | |
ATE535235T1 (de) | Galanthamin-haltiges arzneimittel mit kontrollierter freisetzung | |
CR6858A (es) | Composiciones de eletriptan en forma de particulas que muestra el curso sigmoideo de liberacion controlada | |
FR2890862B1 (fr) | Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique. | |
WO2007062262A3 (en) | Gelatinous medicament formulation and method of administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2313 DE 05/05/2015 |